HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

BLSM — BlossomHill Therapeutics Inc.

BLSM (BlossomHill Therapeutics Inc.) stock: $13.50, $429.1M market cap, $95.4M cash, $333.7M EV, $451.3M fully diluted market cap. Lead program: BH-30643 (NSCLC (Advanced Non-small Cell Lung Cancer)), Phase 2. Data from Fully Diluted's biotech stocks database.

What they do

BlossomHill Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. The Company was incorporated in the State of Delaware on June 22, 2020, and its principal operations are in San Diego, California.

Source: 10-Q FY2026 via SEC EDGAR

Share price
$13.50
Market cap
$429.1M
Cash
$95.4M
Enterprise value
$333.7M

Balance sheet

Cash$95.4M
Debt$0.0M
Net cash$95.4M
Enterprise value$333.7M
Basic shares31.8M shares
Fully diluted shares33.4M shares
Fully diluted market cap$451.3M
Cash per share$3.00
Quarterly burn$22.1M
Cash runway4.3 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common
31.8M
Pre-funded warrants
0.0M
Options
1.3M
RSUs
0.0M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.3M
FDSO
33.4M

Cap table as of 2026-06-30.

Price history

Loading BLSM daily closes…

Loading price history…

Recently reported

BH-30643 Phase 1/2 Positive · 2026-09-15
SOLARA · nsclc (advanced non-small cell lung cancer)
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego